1. Ueki A, Yoshida R, Kosaka T, Matsubayashi H Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers. J Hum Genet. 2023. https://doi.org/10.1038/s10038-023-01153-1. Online ahead of print.
2. Usui Y, Taniyama Y, Endo M, Koyanagi YN, Kasugai Y, Oze I, et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N Engl J Med; 388: 1181-90.
3. Robert ME, Ranola JMD, Marshall ML, Susswein LR, Graceffo S, Bohnert K, et al. Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol. 2019;5:1325–31.
4. Ajani JA, D’Amico TA, Bentrum DJ, Cooke D, Corvera C, Das P, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Gastric Cancer. Version 1.2023-March 10, 2023.
5. Helicobacter pylori eradication as a strategy for preventing gastric cancer. Vol. 8. IARC Working Group Report. Lyon, France: International Agency for Research on Cancer, 2014 (https://publications.iarc.fr/Book-And-Report-Series/Iarc-Working-Group-Report/-Em-Helicobacter-Pylori-Em-Eradication-As-A-Strategy-For-Preventing-Gastrc-Cancer-2014).